Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TNXP Tonix Pharmaceuticals Holding Corporation

0.02 (5.26%)
Dec 08 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 2,273,491
Bid Price 0.40
Ask Price 0.448
News (1)
Day High 0.4209


52 Week Range


Day Low 0.3825
Company Name Stock Ticker Symbol Market Type
Tonix Pharmaceuticals Holding Corporation TNXP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.02 5.26% 0.40 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.395 0.3825 0.4209 0.398 0.38
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,468 2,273,491 $ 0.3957559 $ 899,747 - 0.3724 - 9.8125
Last Trade Time Type Quantity Stock Price Currency
19:59:43 25 $ 0.4079 USD

Tonix Pharmaceuticals Holding Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
9.3M 23.85M - 0 -116.88M -4.90 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tonix Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No TNXP Message Board. Create One! See More Posts on TNXP Message Board See More Message Board Posts

Historical TNXP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.530.555750.37240.43987032,209,758-0.13-24.53%
1 Month0.470.555750.37240.4543834859,539-0.07-14.89%
3 Months0.920.930.37240.5181192501,833-0.52-56.52%
6 Months1.881.990.37240.8386412451,556-1.48-78.72%
1 Year2.33889.81250.37243.682,132,050-1.94-82.9%
3 Years4.37529.93750.37245.2412,030,082-3.98-90.86%
5 Years181.25262.49380.37247.189,741,028-180.85-99.78%

Tonix Pharmaceuticals Description

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.

Your Recent History

Delayed Upgrade Clock